Also known as: FOXO4-D-Retro-Inverso, Proxofim, FOXO4 DRI, FOXO4DRI, foxo4 dri peptide
Senolytic therapy - selective elimination of senescent cells for anti-aging
Amount
Highly variable - no established human dose. Research community protocols range from 3-25 mg per injection.
Frequency
Intermittent 'hit-and-run' schedule: every other day for 3-6 doses per cycle
Duration
Short cycles of 3-6 doses, repeated 1-3 times per year
Route
SCSchedule
Intermittent 'hit-and-run' schedule: every other day for 3-6 doses per cycle
Timing
No specific time of day established
Duration
Short cycles of 3-6 doses, repeated 1-3 times per year
Repeatable
Yes
Course-based protocol with rest periods
Diluent: Bacteriostatic water
CBC with differential
When: Baseline
Why: Baseline blood counts; senescent cell clearance may cause transient inflammation
CMP
When: Baseline
Why: Liver and kidney function baseline (kidneys showed improvement in mouse studies)
hs-CRP or IL-6
When: Baseline
Why: Baseline inflammatory markers; senescent cell clearance expected to reduce SASP
Serum creatinine and BUN
When: Baseline
Why: Baseline renal function (mouse studies showed renal improvement)
p16INK4a (if available)
When: Baseline
Why: Senescence biomarker (research-grade test)
CMP
When: 1 week after each treatment cycle
Why: Monitor renal and hepatic function
Get free access to all content plus biweekly research updates.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
FOXO4-DRI is a synthetic peptide designed to selectively eliminate senescent cells -- aged, damaged cells that have permanently exited the cell cycle but resist normal programmed cell death. The peptide was developed by a research team led by Peter de Keizer at the Erasmus University Medical Center in Rotterdam, Netherlands, with the seminal findings published in the journal Cell in 2017 by Baar et al. The name FOXO4-DRI reflects both its molecular target (the FOXO4 transcription factor) and its structural design (D-Retro-Inverso modification).
The peptide has a molecular weight of approximately 4826.5 Da and is constructed using the D-Retro-Inverso (DRI) approach, in which the original L-amino acid sequence of the FOXO4-p53 binding interface is reversed in order and synthesized using D-amino acids rather than the naturally occurring L-forms. This DRI modification preserves the spatial orientation of amino acid side chains, allowing the peptide to mimic the binding surface of the native protein while conferring substantial resistance to degradation by cellular proteases that have evolved to cleave L-amino acid peptide bonds.
FOXO4-DRI belongs to the emerging class of senolytic agents -- compounds that selectively kill senescent cells. Cellular senescence is a state of irreversible growth arrest accompanied by a pro-inflammatory secretory phenotype (the senescence-associated secretory phenotype, or SASP). The accumulation of senescent cells in tissues during aging and in response to various stressors is increasingly recognized as a key driver of age-related pathology, chronic inflammation, and functional decline. By selectively targeting these cells for elimination, senolytic agents aim to restore tissue function and potentially reverse aspects of aging.
FOXO4-DRI is also known by the name Proxofim, though this designation has been used primarily in popular and commercial contexts rather than in the peer-reviewed literature.
The mechanism of FOXO4-DRI centers on a specific protein-protein interaction between the Forkhead box O4 (FOXO4) transcription factor and the tumor suppressor protein p53. In senescent cells, p53 plays a dual role: it helps initiate and maintain the senescent state, but it also retains the capacity to trigger apoptosis. The fate decision between senescence (survival with growth arrest) and apoptosis (cell death) depends on the intracellular localization and binding partners of p53.
In senescent cells, FOXO4 expression is upregulated and FOXO4 becomes enriched in promyelocytic leukemia (PML) nuclear bodies, where it forms a complex with p53. This FOXO4-p53 interaction sequesters p53 within PML bodies and shifts the p53 transcriptional program away from pro-apoptotic targets (such as BAX, PUMA, and NOXA) and toward cell cycle arrest targets (such as p21/CDKN1A). The net effect is that senescent cells survive despite harboring activated p53, because FOXO4 diverts p53 from its apoptotic program.
Critically, this FOXO4-p53 interaction is highly enriched in senescent cells and is largely absent in proliferating or quiescent non-senescent cells. This differential dependence provides the basis for selectivity: disrupting the FOXO4-p53 complex preferentially affects senescent cells that rely on this interaction for survival, while sparing healthy cells in which FOXO4-p53 binding does not play a survival role.
FOXO4-DRI functions as a competitive inhibitor of the endogenous FOXO4-p53 interaction. The peptide is derived from the segment of the FOXO4 protein that mediates direct binding to p53. By mimicking this binding surface, FOXO4-DRI competes with endogenous FOXO4 for p53 binding, effectively displacing FOXO4 from the complex.
When the FOXO4-p53 complex is disrupted, p53 is released from PML nuclear bodies and relocates to the mitochondria and other cellular compartments where it can engage the intrinsic apoptotic pathway. Specifically, p53 promotes mitochondrial outer membrane permeabilization (MOMP) through interactions with Bcl-2 family proteins, leading to cytochrome c release, caspase activation, and apoptotic cell death. The senescent cell, deprived of its FOXO4-mediated survival mechanism, undergoes targeted elimination.
The DRI approach addresses a fundamental challenge in peptide therapeutics: susceptibility to proteolytic degradation. Native L-amino acid peptides are rapidly cleaved by cellular and circulating proteases, limiting their half-life and bioavailability. The DRI strategy reverses both the chirality (L to D) and the sequence order of the peptide. Because D-amino acids are not recognized by most mammalian proteases, the resulting peptide is substantially more resistant to enzymatic degradation.
The reversal of sequence order compensates for the change in backbone directionality caused by using D-amino acids, preserving the topological arrangement of side chain functional groups. The net result is a peptide that presents a similar binding surface to the target protein (in this case, p53) while being far more metabolically stable than its L-amino acid counterpart. However, the structural mimicry achieved by DRI peptides is not perfect, and some loss of binding affinity or selectivity can occur depending on the specific protein interface being mimicked.
The foundational preclinical evidence for FOXO4-DRI comes from the 2017 publication by Baar, Brandt, Putavet et al. in Cell. This study reported several key findings that established the proof of concept for FOXO4-DRI as a senolytic agent.
In cell culture, FOXO4-DRI selectively induced apoptosis in senescent human fibroblasts (induced by irradiation, oncogene activation, or replicative exhaustion) while sparing proliferating and quiescent non-senescent cells. The selectivity ratio was striking, with senescent cells showing approximately 10-fold greater sensitivity to FOXO4-DRI-induced apoptosis compared to control cells.
In naturally aged mice (over 24 months old), systemic administration of FOXO4-DRI three times per week for several weeks produced measurable restoration of fitness markers. Treated mice showed improved fur density (reversing age-related fur loss), increased exploratory behavior, and enhanced renal function as measured by serum creatinine and urea nitrogen levels. Histological analysis revealed reduced markers of cellular senescence (p16INK4a expression, senescence-associated beta-galactosidase activity) in the kidneys and livers of treated animals.
In a chemotherapy-induced senescence model, mice treated with doxorubicin (which causes widespread cellular senescence) showed improved recovery and reduced tissue damage when subsequently treated with FOXO4-DRI, further supporting the selective senolytic mechanism.
The therapeutic rationale for FOXO4-DRI is grounded in the growing understanding of cellular senescence as a driver of aging and age-related disease. Senescent cells accumulate in tissues with advancing age and at sites of chronic pathology. Despite being growth-arrested, these cells are metabolically active and secrete a complex mixture of pro-inflammatory cytokines (IL-6, IL-8, IL-1beta), matrix metalloproteinases (MMPs), growth factors (VEGF, PDGF), and chemokines collectively termed the senescence-associated secretory phenotype (SASP).
The SASP drives chronic sterile inflammation ("inflammaging"), promotes tissue remodeling and fibrosis, and can induce senescence in neighboring cells through paracrine signaling. Landmark studies by Baker et al. (2011, 2016) using the INK-ATTAC transgenic mouse model demonstrated that genetic elimination of p16-positive senescent cells extended median lifespan by approximately 25% and delayed the onset of age-related pathologies including cataracts, sarcopenia, and lipodystrophy.
FOXO4-DRI represents a distinct approach compared to the more widely studied small-molecule senolytic combinations. The most prominent small-molecule senolytic regimen is dasatinib plus quercetin (D+Q), which targets the anti-apoptotic networks (particularly the Bcl-2/Bcl-xL and PI3K/AKT pathways) that protect senescent cells from apoptosis. Navitoclax (ABT-263), a Bcl-2/Bcl-xL inhibitor, is another well-studied senolytic compound.
FOXO4-DRI differs from these approaches in several respects. Its selectivity mechanism is fundamentally different, targeting the FOXO4-p53 interaction rather than broadly acting anti-apoptotic pathways. This may provide a distinct selectivity profile, potentially reducing off-target effects on non-senescent cells that also depend on Bcl-2 family proteins for survival (a known concern with navitoclax, which causes dose-limiting thrombocytopenia). However, as a large peptide, FOXO4-DRI faces greater pharmacokinetic challenges including limited oral bioavailability, requirement for parenteral administration, potential immunogenicity, and higher manufacturing costs.
The most significant limitation of the FOXO4-DRI evidence base is that the foundational findings derive primarily from a single research group. As of the current literature, independent replication of the in vivo efficacy data by other laboratories has been limited. The gold standard for establishing a therapeutic concept requires robust, independent reproduction of key results, and this has not yet been achieved for FOXO4-DRI.
FOXO4-DRI remains entirely at the preclinical stage with no human clinical trials initiated or registered. Fundamental questions regarding human pharmacokinetics, bioavailability, dosing, tolerability, immunogenicity, and efficacy remain unanswered. The translation from mouse studies to human therapeutics in the senolytic field is particularly uncertain, as the dynamics of senescent cell accumulation, the composition of the SASP, and the consequences of senescent cell clearance may differ significantly between species.
As a peptide of approximately 4.8 kDa, FOXO4-DRI is too large for oral absorption and requires parenteral administration. Its D-amino acid composition confers protease resistance but may also impair cellular uptake, as the peptide must penetrate cell membranes to reach intracellular FOXO4-p53 complexes. The mechanisms by which FOXO4-DRI achieves intracellular access have not been fully characterized, and the in vivo tissue distribution, half-life, and clearance kinetics remain poorly defined.
Cell-penetrating properties may be facilitated by the peptide's sequence characteristics, but the efficiency of intracellular delivery across different tissue types is unknown. This is particularly relevant for targeting senescent cells embedded in dense fibrotic tissue, where penetration barriers may limit efficacy.
The long-term consequences of senescent cell elimination are not fully understood. While the prevailing evidence supports the benefit of senescent cell clearance, some contexts exist where senescent cells play beneficial roles, including wound healing, tumor suppression, and tissue remodeling during development. A non-discriminating senolytic agent could theoretically interfere with these protective functions. The selectivity of FOXO4-DRI for different subtypes of senescent cells and its effects in the context of acute injury, active tumorigenesis, or tissue repair have not been systematically evaluated.
Additionally, the immunogenicity potential of a D-amino acid peptide administered repeatedly over time is unknown. While D-amino acid peptides are generally considered less immunogenic than their L-counterparts, the adaptive immune response to repeated administration of a novel synthetic peptide has not been characterized in preclinical immunogenicity studies.
The full molecular formula and CAS number for FOXO4-DRI have not been established in the public literature. The exact sequence, while based on the FOXO4-p53 binding domain, has been reported with some variation in secondary sources. This incomplete molecular characterization complicates efforts to standardize research-grade material and to compare results across studies that may use different peptide preparations.
Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging, published in Cell (Baar MPA et al., 2017; PMID: 28340339):
Foundational study demonstrating that FOXO4-DRI selectively targets senescent cells by disrupting the FOXO4-p53 interaction, inducing p53-dependent apoptosis in senescent but not healthy cells. In aged mice, systemic FOXO4-DRI treatment restored fitness, fur density, and renal function.
We summarize new studies, safety updates, and dosing insights โ delivered biweekly.
See real-world usage patterns alongside the clinical evidence above. Community-sourced, not clinically verified.
Based on 15+ community reports
View community protocolsResearch-grade suppliers verified by our scoring methodology.
OS-01 (Peptide 14) is a senotherapeutic decapeptide targeting cellular senescence via PP2A modulation. Published RCT data shows skin barrier and aging improvements.
PNC-27: p53-derived anticancer peptide guide. Covers selective HDM-2 binding on cancer membranes, pore-forming cytotoxicity, and research limitations.
Epitalon: Telomerase-activating anti-aging tetrapeptide. Covers telomere elongation, pineal gland modulation, Khavinson research, and dosing data.
SS-31 (Elamipretide): Cardiolipin-targeting mitochondrial peptide. Covers Barth syndrome Phase 3 data, heart failure research, dosing, and trial results.
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.
Epitalon for preventive longevity research targeting telomere maintenance with a broader evidence base; FOXO4-DRI for interventional senescent cell clearance research with a novel but less validated mechanism
Tat-Beclin-1 has stronger evidence through genetic lifespan data and human centenarian correlations, plus broader hallmark coverage through autophagy's connections to multiple aging pathways. FOXO4-DRI offers a more dramatic intervention by eliminating entire senescent cells, addressing the SASP directly. Both are entirely preclinical with no human trials.
Research review of anti-aging peptides organized by mechanism of action including senolytic peptides (FOXO4-DRI), telomere peptides (epitalon), mitochondrial peptides (SS-31, MOTS-c), tissue remodelers (GHK-Cu), and bioregulators (pinealon, thymalin). Evidence quality assessment for each approach.
A comprehensive guide explaining peptide research phases from preclinical studies to FDA approval. Learn how to evaluate evidence quality using real peptide examples, understand what research status badges mean, and use the Evidence Explorer tool.
Definitive mapping of the 12 hallmarks of aging to specific peptide interventions including Epitalon, FOXO4-DRI, SS-31, MOTS-c, and NAD+.
From senolytic FOXO4-DRI to mitochondrial SS-31, we ranked 13 anti-aging peptides by clinical trial evidence across 6 mechanisms. See which have human data vs. animal-only studies.
Related content you may find interesting